Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.

Sirui MaSoumon RudraJian L CampianJeffrey R MillmanGavin P DunnTanner JohannsMichael GoldsteinAlbert H KimJiayi Huang

Published in: Neuro-oncology advances (2020)

Criteria for mGBM may require further refinement and validation. CDKN2A/B deletion, but not TERT mutation or EGFR amplification, may be an independent prognostic biomarker for IDH-wildtype GBM patients.

Keyphrases

small cell lung cancer
end stage renal disease
epidermal growth factor receptor
tyrosine kinase
ejection fraction
newly diagnosed
chronic kidney disease
low grade
prognostic factors
wild type
label free
single molecule
patient reported